Author

Zhifang Ma

Observed name: Ma, Zhifang

Institution: First Hospital of Shanxi Medical University

Observed institutions: Shenyang Agricultural University, Shanxi Medical University, First Hospital of Shanxi Medical University, Second Hospital of Shanxi Medical University

ORCID: 0000-0003-4946-2276

Observed ORCID: 0000-0003-4946-2276

OpenAlex ID: A5065503406

A Cuproptosis-Related lncRNAs Signature Could Accurately Predict Prognosis in Patients with Clear Cell Renal Cell Carcinoma

2022 · Wei Zhang, Han Wang, et al. · Analytical Cellular Pathology · 11

Newly identified adverse events for gemcitabine using the Food and Drug Administration Adverse Event Reporting System

2023 · Wei Zhang, Yuhong Wang, et al. · Expert Opinion on Drug Safety · 6

Expression and role of CNIH2 in prostate cancer

2024 · Wei Zhang, Zhenhua Li, et al. · Scientific Reports · 2

Newly identified adverse events of enzalutamide using the food and drug administration adverse event reporting system

2023 · Xin Wang, Lina Chang, et al. · Expert Opinion on Drug Safety · 2

Drugs causing prostate-specific antigen changes: the food and drug administration adverse event reporting system combined with Mendelian randomization analysis

2024 · Wei Zhang, Xin Jiang, et al. · Expert Opinion on Drug Safety · 1

Downregulation of ENPP4 Is Associated with Poor Prognosis and Enhanced Malignant Phenotypes in Clear Cell Renal Cell Carcinoma

2026 · Wenjie Yang, Chenxi Li, et al. · Research Square

Integrated analysis of single-cell and bulk RNA sequencing predicts prognosis and therapeutic response using malignant epithelial cells marker genes in bladder cancer

2024 · Caoyang Hu, Wei Zhang, et al. · Research Square

A necroptosis-related lncRNA signature can accurately predict the survival outcome of bladder cancer patients

2022 · Zhifang Ma, Wei Zhang, et al. · Research Square

Works count: 12

Citation count: 22

H-index: 2

I10-index: 1